Ovoca Bio PLC - Publication of 2024 Annual Report
Ovoca Bio plc
("Ovoca" or the "Company")
Publication of 2024 Annual Report
https://ovocabio.com/results-reports-presentations/
2024 Highlights:
During 2024, the Ovoca management team focused on the following key areas:
· Evaluation of the value of the IP and if there was a possibility of recouping any financial value in the sale of IP held by the Company. It was previously determined that the value of the IP was impossible to ascertain accurately, and consequently Management made the decision to write it down to zero. The efforts shifted to the investigation of potential new opportunities for the business.
· Due to the end of Orenetide R&D and the write off of its related IP, it was critically important for the Company to manage its financial resources carefully throughout 2024. The Management and the Board have worked to lower costs, mainly related to R&D activities being suspended, to ensure the Company has sufficient funding to cover its expenditure as required and remain a going concern.
Letter from the CEO
Dear Shareholders of Ovoca Bio Plc,
This is our 2024 Full Year Annual Report. The Company experienced significant changes during the course of the year upon the unsuccessful Clinical Trials results which was announced on
As part of that effort, the Company has been active in winding-down the corporate infrastructure put in place since 2018 to support the development of Orenetide, the Company's proprietary peptide. Subsidiaries in
I acquired a large stake in the Company in
I would like to take this opportunity to thank the whole team at the Company and the members of the Board of Directors for their perseverance, hard work and invaluable contribution to the further development of Ovoca.
Annual Report
The Annual Report and Financial Statements will be posted to shareholders today and are also available online at the Company's website, www.ovocabio.com.
End
For further information:
Ovoca Bio plc
Tel +353 1 661 9819
Beaumont Cornish Limited (Nominated Adviser and Broker)
Tel: +44 (0) 207 628 3396
Nominated Adviser Statement
Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated Adviser and is authorised and regulated in the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE